Alpha Cognition announced that the Army Medical Research and Material Command has awarded the company a $750,000 grant to support a pre-clinical study of the possible use of ALPHA-1062 Intranasal galantamine for the treatment of blast-induced mild traumatic brain injury (mTBI). According to Alpha Cognition, the study will be conducted in partnership with the Seattle Institute for Biomedical and Clinical Research. ALPHA-1062 is currently in development for the treatment of Alzheimer’s disease.
According to Alpha Cognition, the pre-clinical study is expected to start later this year and will take place over 16 months. The company said that a different pre-clinical study has already demonstrated that ALPHA-1062 can improve cognition and movement.
Alpha Cognition Chief Scientific Officer Denis Kay explained, “The body of evidence is growing to show that people who have suffered a TBI, even a mild TBI, are at greater risk of developing dementia in later life and are at risk for additional neurocognitive issues. An integral part of this research program will evaluate ALPHA-1062’ ability to reduce a toxic form of a brain protein, tau, known to be increased in this military relevant TBI model. Accumulation of toxic tau in the brain is linked to dementia progression, and was previously shown to be decreased by ALPHA-1062 in a separate pre-clinical model of moderate TBI. We are excited to embark upon a trial to provide additional evidence for reduction of one of the neuropathological drivers of increased dementia risk.”
Read the Alpha Cognition press release.
